GWM
MDGL icon

Geneos Wealth Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Geneos Wealth Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed -$4K – 2830
2021
Q3 		$4K Hold
50
– – ﹤0.01% 2512
2021
Q2 		$4K Buy
+50
New +$5.92K ﹤0.01% 2513

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Geneos Wealth Management's MDGL Position: Q4 2021 in Review

Geneos Wealth Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2021, closing a stake of 50 shares — an estimated $4K sold.

Geneos Wealth Management first reported a position in MDGL in Q2 2021 and held it in 2 quarters. The position peaked at $4K in Q3 2021. 144 funds tracked by Wall St. Rank hold MDGL as of Q4 2021.

  • Geneos Wealth Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 50 Madrigal Pharmaceuticals shares in Q4 2021, an estimated $4K.
  • Geneos Wealth Management first reported a position in Madrigal Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Geneos Wealth Management's Madrigal Pharmaceuticals position peaked at $4K in Q3 2021.
  • 144 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2021.

Based on Geneos Wealth Management's 13F filing for Q4 2021, filed 9 Feb 2022.